IPH: Key assets advance toward pivotal data and regulatory milestones, driven by strategic partnerships
The discussion highlighted a focused strategy on three core assets, with major milestones expected for lacutamab, IPH4502, and monalizumab by year-end. Strategic partnerships, innovative ADC development, and upcoming pivotal data readouts position the pipeline for significant progress.Based on Inna…